Sigyn Therapeutics Stock Price, News & Analysis

Sigyn Therapeutics, Inc. (OTCQB: SIGY) is a development-stage medical technology company based in San Diego, California. The company is pioneering blood purification technologies to address pathogen-associated inflammatory disorders, which are not effectively treated by traditional drug therapies.

Sigyn's flagship product, Sigyn Therapy™, targets a range of severe medical conditions including endotoxemia, sepsis, community-acquired pneumonia, and infections by drug-resistant bacteria and viruses. The initial clinical focus is on end-stage renal disease (ESRD) patients suffering from endotoxemia, a prevalent condition linked to increased mortality.

Further broadening its innovative portfolio, Sigyn Therapeutics is also developing ImmunePrep™, ChemoPrep™, and ChemoPure™. ImmunePrep™ aims to improve the efficacy of immunotherapeutic antibodies, a market projected to grow exponentially. ChemoPrep™ is designed to enhance the delivery and reduce the toxicity of chemotherapy, addressing a crucial need as less than 5% of chemotherapy reaches the tumor site. ChemoPure™ further mitigates chemotherapy toxicity by extracting off-target drugs from the bloodstream post-treatment.

Despite its development-stage status, Sigyn has demonstrated promising in vitro results, reducing the prevalence of multiple pathogen and inflammatory targets in human blood plasma. The company has initiated steps to begin first-in-human studies and is in the process of finalizing study protocols for Sigyn Therapy™ in ESRD patients.

On the financial front, Sigyn reported a net loss of approximately $4.1 million for the year ending December 31, 2023, indicating its commitment to research and development. The company recently completed a 1-for-40 reverse stock split, a strategic move aimed at meeting Nasdaq listing requirements.

Sigyn Therapeutics continues to advance its mission, positioning itself as a leader in the medical technology field with a comprehensive pipeline aimed at improving patient outcomes and addressing unmet medical needs.